2 citations
,
June 2009 in “PubMed” 2 citations
,
February 2007 in “PubMed” This study found that patients on dutasteride had $20.50 lower monthly medical costs compared to those on finasteride.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.
21 citations
,
October 2015 in “Current Drug Targets” This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.
23 citations
,
June 1999 in “Clinical Therapeutics” In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.